| Gilead Sciences Switzerland Sàrl - Sunlenca, Injektionslösung |
| 68385 | | 01 | | Sunlenca | | Injektionslösung | | J05AX31 | | Lenacapavir | | 07.07.2023 | | |
|
| Composition |
| lenacapavirum 463.5 mg ut lenacapavirum natricum, macrogolum 300, aqua ad iniectabile, ad solutionem pro 1.5 ml corresp. natrium 10.99 mg. |
| Packungsbestandteile |
| Injection solution | | | | | | | | Active Agent | Dose |
|---|
| Lenacapavirum | 463.5mg / 1.5ml |
| | BAG: Active Agent | Dose |
|---|
| Lenacapavirum | 463.5 mg |
| | | | Inactive agents | Dose |
|---|
| Macrogol | 300 |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | 2 | 19883.88 | 20708.65 | A | SL | No |
|
